SCHEMBL31118648

SCHEMBL31118648

O=c1ccc2cc(Cl)cc(C(F)(F)F)c2[nH]1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
F11 P03951 1/20 0.46
HCAR1 Q9BXC0 5/20 0.44
CA12 O43570 3/20 0.42
CA9 Q16790 3/20 0.42
AKR1B1 P15121 1/20 0.35
AR P10275 3/20 0.35
MEN1 O00255 3/20 0.35
ALDH1A1 P00352 3/20 0.35
HPGD P15428 3/20 0.35
KMT2A Q03164 3/20 0.35
KDM4E B2RXH2 2/20 0.35
LMNA P02545 2/20 0.35
HTT P42858 2/20 0.35
KIF11 P52732 1/20 0.35
GLA P06280 1/20 0.35
GAA P10253 1/20 0.35
CRHBP P24387 1/20 0.35
CRHR2 Q13324 1/20 0.35
SMN1; SMN2 Q16637 2/20 0.33
THRB P10828 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20660673 0.83 CA12 (0.44) HCAR1CA12CA9ARMEN1
SCHEMBL19751539 0.80 CA12 (0.46) HCAR1CA12CA9ARALDH1A1
SCHEMBL15828550 0.78 HCAR1 (0.37) HCAR1CA12CA9ARALDH1A1
SCHEMBL29153243 0.77 CA12 (0.58) F11HCAR1CA12CA9AKR1B1
SCHEMBL3434396 0.74 DAO (0.47) ALDH1A1KMT2AKDM4EGAA
SCHEMBL5134130 0.74 CA12 (0.59) HCAR1CA12CA9AKR1B1MEN1
SCHEMBL31142828 0.74 F11 (0.50) F11HCAR1CA12CA9AKR1B1
SCHEMBL7325829 0.73 HCAR1 (0.37) HCAR1CA12CA9ARHPGD
SCHEMBL4707291 0.69 GRIN1 (0.59) MEN1ALDH1A1HPGDKMT2AKDM4E
SCHEMBL8975943 0.69 HCAR1 (0.41) F11HCAR1CA12CA9AR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4680607-A1 BICYCLIC UREAS AS KINASE INHIBITORS Incyte Corporation (US) 2026-01-21 EP disclosed
US-20250304582-A1 Bicyclic Ureas As Kinase Inhibitors INCYTE CORPORATION 2025-10-02 US disclosed
US-20240317744-A1 Bicyclic Ureas As Kinase Inhibitors INCYTE CORPORATION 2024-09-26 US disclosed
WO-2024191996-A1 BICYCLIC UREAS AS KINASE INHIBITORS INCYTE CORPORATION (US) 2024-09-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250304582-A1 Bicyclic Ureas As Kinase Inhibitors JAK2, UCK2, ULK2 F11 4133/4885HCAR1 2871/4885CA12 4580/4885
US-20240317744-A1 Bicyclic Ureas As Kinase Inhibitors JAK2, UCK2, ULK2 F11 4133/4885HCAR1 2871/4885CA12 4580/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.